Amarantus BioScience Holdings, Inc. – "MANF Continues to Deliver Heading into 2H-14"

Publishing & Media

Share Tweet

Amarantus BioScience Holdings, Inc. – "MANF Continues to Deliver Heading into 2H-14"

New York, NY / June 30, 2014 / Amarantus BioScience Holdings, Inc. (OTCQB: AMBS) today published a new blog post on The Chairman's Blog, written by the Company's CEO, Mr. Gerald Commissiong. is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his blog, Mr. Commissiong provides insight into how the "MANF story" has unfolded over the past two years in conjunction with both LymPro and Eltoprazine. He comments, "Reproducibility is the hallmark of good science, and to date MANF has reproducibly demonstrated activity consistent with a breakthrough treatment across a highly valuable spectrum of indications." Read the full blog post from Mr. Gerald Commissiong on (

About Amarantus BioScience Holdings, Inc.

Amarantus BioScience Holdings (AMBS) is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis. AMBS has licensed Eltoprazine ("Eltoprazine"), a phase 2b ready indication for Parkinson's Levodopa induced dyskinesia and Adult ADHD. AMBS has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test(R)") for Alzheimer's disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. AMBS also owns intellectual property for the diagnosis of Parkinson's disease ("NuroPro") and the discovery of neurotrophic factors ("PhenoGuard"). Amarantus operations are located at Janssen Labs @QB3 in San Francisco, CA. For further information please visit, or connect with the Company on Facebook, LinkedIn, Twitter and Google+.

About is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment.